Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Inclusion Criteria:

• Age ≥18 years

• CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (EuropeanLeukemia Network [ELN] 2020 criteria; Baccarani et al 2013) with confirmation of aPhiladelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed byFISH.Criteria must meet the definition of chronic phase CML

• BCR ::ABL1 transcript quantifiable by quantitative PCR

• 1st-line treatment with tyrosine kinase inhibitor

• No tyrosine kinase inhibitor or hydroxyurea treatment received prior to first bloodsampling (at diagnosis)

• Signature of informed consent for CML Observatory and signature of informed consentfor BIO-TIMER protocol

• Read and understand French

• Enrolled in a social security plan or beneficiary of such a plan

Exclusion Criteria:

• CML in accelerated or blast phase

• Refusal to participate in the study

• Treatment started prior to inclusion

• Patients under guardianship, curatorship, deprivation of liberty or safeguard ofjustice

• Pregnant or breast-feeding women